Pfizer will buy the stake in Valneva, which is also working on its COVID-19 vaccine, at a price of 9.49 euros per share, via a reserved capital increase.Register now for FREE unlimited access to Reuters.comValneva will use the proceeds from Pfizer’s equity investment to support its Phase 3 development contribution to the Lyme disease program.
"Pfizer's investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva's vaccine expertise," said Valneva chief executive Thomas Lingelbach.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:
Get some more jabs in you. The 8th or 9th booster will work